<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11859476</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.480</article-id><article-id pub-id-type="other">EPP0301</article-id><article-id pub-id-type="pii">S0924933824004802</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Ketamine enhanced ECT in refractory recurrent depression.</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Arribas-Simon</surname><given-names>B.</given-names></name><xref rid="aff1041" ref-type="aff">
<sup>1</sup></xref><xref rid="cor0341" ref-type="corresp">
<sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Martinez.Gimeno</surname><given-names>P.</given-names></name><xref rid="aff1041" ref-type="aff">
<sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Calvo-Valcarcel</surname><given-names>M.</given-names></name><xref rid="aff1041" ref-type="aff">
<sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Alario-Ruiz</surname><given-names>C.</given-names></name><xref rid="aff1041" ref-type="aff">
<sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Martin-Santiago</surname><given-names>O.</given-names></name><xref rid="aff1041" ref-type="aff">
<sup>1</sup></xref></contrib></contrib-group><aff id="aff1041">
<sup>1</sup><institution>Hospital Clinico Universitario</institution>, <city>Valladolid</city>, <country>Spain</country>
</aff><author-notes><corresp id="cor0341">
<label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="455">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S225</fpage><lpage>S225</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824004802a.pdf"/><abstract><sec id="sec2047"><title>Introduction</title><p>Recurrent Depressive Disorder is a chronic condition that significantly impacts the quality of life. Despite various treatment options, some patients face severe and treatment-resistant relapses. This case is related to research on ketamine in Electroconvulsive Therapy (ECT) for RDD. One study highlighted the efficacy and safety of ketamine compared to other anaesthetic agents in ECT for major depression. Additionally, another study explored subanesthetic doses of ketamine before each ECT session to improve therapeutic outcomes and sleep quality in patients with major depressive disorder.</p></sec><sec id="sec2048"><title>Objectives</title><p>To present a clinical case of a patient with Recurrent Depressive Disorder (RDD) who improved following a change in the Electroconvulsive Therapy (ECT) protocol using ketamine as an anaesthetic inducer.</p></sec><sec id="sec2049"><title>Methods</title><p>
We examined the patient&#x02019;s medical records, including her medical history, previous treatments, and therapeutic responses.</p></sec><sec id="sec2050"><title>Results</title><p>A 65-year-old childless woman with a history of stroke, bilateral carotid atheromatosis, and hypothyroidism suffered from RDD. Despite multiple prior treatments and ECT, she experienced a severe depressive relapse. Eight intensive ECT sessions were administered, with observed memory lapses. Due to the lack of response, the anaesthetic inducer etomidate was replaced with ketamine, resulting in a positive response. The patient continued pharmacological treatment with improved mood, but recent and evident memory alterations persisted, possibly related to anterograde amnesia.</p></sec><sec id="sec2051"><title>Conclusions</title><p>
This case highlights the complexity of RDD in patients with comorbidities and treatment-resistant relapses. The change in the ECT protocol using ketamine was effective, emphasizing the importance of alternative therapeutic approaches in refractory cases. The successful treatment of RDD in this patient using ketamine in ECT underscores the need for personalized therapeutic options in treatment-resistant patients. These scientific resources reinforce the relevance of exploring therapeutic alternatives in contemporary clinical practice. We need more research to understand the underlying mechanisms and how this approach could be enhanced in similar cases.</p></sec><sec id="sec2052"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>